How would you approach the management of a patient with Stage IV NSCLC harboring both a classical and non-classical compound EGFR mutations?

I was asked to dust off q prior Mednet discussion on frontline treatment selection for patients with a new diagnosis of advanced common EGFR mutation+ NSCLC in light of recent updates on both the key FLAURA2 and MARIPOSA trials. And indeed the timing seems ripe for such not just due to these updates...